A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration

Macular Degeneration Clinical Trial

Official title:

A Multicenter, Open-label, Multiple Dose Study in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Repeat Intravitreal Injections of GEM103

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04643886
• Other study ID #: GEM-CL-10302
• Secondary ID: REGATTA
• Status: Terminated
• Phase: Phase 2
• Start date: July 30, 2020
• Est. completion date: March 21, 2022

Study information

• Verified date: September 2022
• Source: Gemini Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is designed to investigate the safety, PK/PD, biomarker and early clinical effects of repeat GEM103 IVT injections.

Description:

This is a Phase 2a, multi-center, open-label, multiple dose study in subjects with geographic atrophy (GA) secondary to dry Age-related Macular Degeneration (dry AMD) to investigate the safety, PK/PD, biomarker and early clinical effect of GEM103 repeat IVT injections.

Subjects will undergo clinical and ophthalmic assessments for determination of inclusion in the study. Subjects who participated in the Phase 1 Study (GEM-CL-10301) as well as treatment naïve subjects that did not participate in the GEM-CL-10301 Study and who meet all eligibility criteria will be enrolled.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 62
• Est. completion date: March 21, 2022
• Est. primary completion date: February 18, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

1. At least 50 years old at the time of signed informed consent.

2. Must have one of the following genetic profiles:

1. Genetic Profile A.

2. Genetic Profile B.

3. BCVA in the study eye of 24 to 83 letters using ETDRS Chart Visual Acuity (VA) Scale (approximately equivalent to Snellen VA of 20/25 to 20/320).

4. Confirmed diagnosis of GA in the study eye where total size of all GA lesions in the study eye must be within 0.5 to 15.01- and 7- disc areas.

5. Sufficiently clear ocular media and able to cooperate with ophthalmic visual function testing and anatomic assessment in the study eye.

6. Understands the full nature and purpose of the study and provides informed consent prior to initiation of any study procedure; all subjects with a reproductive potential must agree to use effective contraceptive methods through the end of study (EOS) Visit.

Exclusion Criteria:

1. Presence of the following ocular conditions - in the study eye:

1. Any history of exudative Age-related Macular Degeneration or choroidal neovascularization.

2. Any active ocular disease or condition that could confound the assessment of the macula or be a contraindication to IVT injection.

3. Any intraocular surgery, with the exception of stable intraocular lens replacement surgery more than 3 months prior to consent.

4. Aphakia or complete absence of the posterior capsule.

5. History of laser therapy to the macula or fundus or extensive laser to the retina.

6. Prior corneal transplant.

2. Presence of any of the following ocular conditions - in either eye:

1. History of herpetic infection.

2. Concurrent disease that could require medical or surgical intervention during the study period.

3. Active uveitis and/or vitritis (grade: trace or above).

4. History of idiopathic or autoimmune-associated uveitis.

5. Active blepharitis, conjunctivitis, keratitis, episcleritis, scleritis, or endophthalmitis.

6. Any ophthalmologic condition that reduces the clarity of the media and that, in the opinion of the Investigator, interferes with ophthalmologic examination.

3. In the opinion of the Investigator, the subject has any prior or ongoing medical condition (e.g., ocular other than dry AMD, systemic, psychiatric) or clinically significant screening laboratory value that may present a safety risk, interfere with study compliance or study follow-up, or confound data interpretation throughout the follow-up period.

4. Female subjects must not be pregnant or lactating, nor plan to become pregnant during the study.

5. Current use of medications known to be toxic to the lens, retina, or optic nerve.

6. Use of any investigational new drug or other experimental treatment in the last 6 months, and/or receipt of any prior gene therapy (e.g., AAV) or ocular device implantation (other than PCIOL placement following cataract surgery)

Related Conditions & MeSH terms

• Atrophy
• Dry Age-related Macular Degeneration
• Geographic Atrophy
• Macular Degeneration
• Retinal Degeneration
• Retinal Disease
• Retinal Diseases

Intervention

Drug:
• GEM103
Biological

Locations

Country	Name	City	State
United States	Gemini Clinical Trial Site	Abilene	Texas
United States	Gemini Clinical Trial Site	Asheville	North Carolina
United States	Gemini Clinical Trial Site	Augusta	Georgia
United States	Gemini Clinical Trial Site	Bakersfield	California
United States	Gemini Clinical Trial Site	Beverly Hills	California
United States	Gemini Clinical Trial Site	Bloomfield	New Jersey
United States	Gemini Clinical Trial Site	Charlotte	North Carolina
United States	Gemini Clinical Trial Site	Chesterfield	Missouri
United States	Gemini Clinical Trial Site	Dallas	Texas
United States	Gemini Clinical Trial Site	Eugene	Oregon
United States	Gemini Clinical Trial Site	Golden	Colorado
United States	Gemini Clinical Trial Site	Indianapolis	Indiana
United States	Gemini Clinical Trial Site	Marietta	Georgia
United States	Gemini Clinical Trial Site	New London	Connecticut
United States	Gemini Clinical Trial Site	Oak Park	Illinois
United States	Gemini Clinical Trial Site	Oxnard	California
United States	Gemini Clinical Trial Site	Palm Beach Gardens	Florida
United States	Gemini Clinical Trial Site	Phoenix	Arizona
United States	Gemini Clinical Trial Site	Poway	California
United States	Gemini Clinical Trial Site	Rapid City	South Dakota
United States	Gemini Clinical Trial Site	Reno	Nevada
United States	Gemini Clinical Trial Site	Saint Louis	Missouri
United States	Gemini Clinical Trial Site	Saint Petersburg	Florida
United States	Gemini Clinical Trial Site	Santa Barbara	California
United States	Gemini Clinical Trial Site	Santa Maria	California
United States	Gemini Clinical Trial Site	Tallahassee	Florida
United States	Gemini Clinical Trial Site	The Woodlands	Texas
United States	Gemini Clinical Trial Site	Virginia Beach	Virginia
United States	Gemini Clinical Trial Site	Winter Haven	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Gemini Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety of intravitreal (IVT) injections of GEM103, as measured by number of subjects with ocular adverse events.		18 months
Secondary	To describe the clinical effect of GEM103 IVT injection, as the change from baseline in best corrected visual acuity (BCVA) scores as assessed by ETDRS scale.		6 months
Secondary	To evaluate the total CFH levels in aqueous humor after GEM103 IVT injection, whenever possible.		6 months